EcoDrugPlus

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSMLUG00000015152
Gene Symbol: NOD2
4 Cross references
166 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSMLUG00000012582
Gene Symbol: OPRD1
2 Cross references
252 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSMLUG00000015401
Gene Symbol: OPRK1
2 Cross references
262 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSMLUG00000010826
Gene Symbol: OPRM1
2 Cross references
214 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSMLUG00000016492
Gene Symbol: OXTR
2 Cross references
262 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSMLUG00000002160
Gene Symbol: PAK4
2 Cross references
163 Possible Orthologues:

Pancreatic Lipase

Ensembl ID : ENSMLUG00000008080
Gene Symbol: PNLIP
4 Cross references
300 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSMLUG00000009501
Gene Symbol: PTH1R
2 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSMLUG00000010594
Gene Symbol: PPARD
2 Cross references
418 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSMLUG00000017638
Gene Symbol: PPARG
4 Cross references
405 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSMLUG00000009229
Gene Symbol: PIK3CA
2 Cross references
275 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSMLUG00000000124
Gene Symbol: PIK3CB
4 Cross references
215 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).